Several immunotherapies targeting amyloid-β in the brain have now been shown to modestly slow the progression of Alzheimer’s disease if applied at an earlier stage of the condition. This is a long way removed from a cure, particularly given the potentially severe side-effects that accompany brain-targeted monoclonal antibody therapies. Alzheimer’s is a complicated condition, and it seems clear that removing amyloid-β does too little on its own to reduce pathology in the brain. It is contributing, but it is not the only contribution, or perhaps not even the most important contribution. More will be needed in parallel, such as also targeting <a href="https://www.fightaging.org/archives/2023/07/towards-depletion-of-microglia-as-a-treatment-f…
Donanemab Slows Progression of Earlier, Less Severe Alzheimer's Disease
Several immunotherapies targeting amyloid-β in the brain have now been shown to modestly slow the progression of Alzheimer’s disease if applied at an earlier stage of the condition. This is a long way removed from a cure, particularly given the potentially severe side-effects that accompany brain-targeted monoclonal antibody therapies. Alzheimer’s is a complicated condition, and it seems clear that removing amyloid-β does too little on its own to reduce pathology in the brain. It is contributing, but it is not the only contribution, or perhaps not even the most important contribution. More will be needed in parallel, such as also targeting <a href="https://www.fightaging.org/archives/2023/07/towards-depletion-of-microglia-as-a-treatment-f…